|
APUS Apimeds Pharmaceuticals US Inc 1894525 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-20,173,129.00 |
| Balance Sheet |
|
Current Assets
|
$10,678,438.00 |
|
Assets
|
$127,623,697.00 |
|
Current Liabilities
|
$21,073,283.00 |
|
Liabilities
|
$21,175,156.00 |
|
Equity
|
$106,448,541.00 |
|
Shares Out
|
1509118.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-7,734,893.00 |
|
Investing Cash Flow
|
$1,990,606.00 |
| Market Analysis |
Market Cap
|
$4,104,800.96 |
|
Price
|
$2.89 |
|
BVPS
|
70.54 |
|
PB
|
0.04 |
|
EPS
|
-11.77 |
|
FCF
|
$-7,744,287.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-10-01 09:31:48 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-10-26 10:00:36 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view APUS documents filed with the SEC.
APUS Filings
Clear
